Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Bescherming tegen desinformatie over HIV-vaccins bij adolescente meisjes en jonge vrouwen in Zuid-Afrika (PROTECT)

28 augustus 2026 bijgewerkt door: University of Pennsylvania

Adolescent girls and young women (AGYW) between the ages of 15-29 years continue to bear the brunt of Human Immunodeficiency Virus (HIV) infections in South Africa despite progress recorded in prevention and treatment programmes. The ongoing susceptibility of young women to HIV infection and the sub-optimal uptake of prevention options such as Pre-Exposure Prophylaxis (PrEP) that are highly effective creates a need for an HIV vaccine to benefit populations at substantial risk of HIV infection. However, lessons from previous vaccine studies and the recent COVID-19 vaccine have highlighted significant barriers to vaccine uptake, such as widespread misinformation and vaccine hesitancy. These challenges threaten the successful implementation of a future HIV vaccine. Building on these insights, this study will utilise psychological inoculation theory to develop and evaluate HIV vaccine messages among adolescent girls and young women. Primary objective: To compare changes in intentions to receive HIV vaccine following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.

Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about the HIV vaccine in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

2163

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Johannesburg, Zuid-Afrika
        • Health Economics and Epidemiology Research Office, University of the Witwatersrand

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 29 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Female
  • Age 18-29 years
  • Self-reported history of sexual activity in the past 12 months
  • Self-reported HIV-negative status or unknown HIV status at enrolment
  • Willing and able to provide written informed consent
  • Able to read and understand English

Exclusion Criteria:

  • Unwilling or unable to provide consent for study participation.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Control

Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.

Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.

Ander: Enhanced inoculation message

Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime.

Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
HIV Vaccine Intention, at the End of the Baseline Assessment
Tijdsspanne: At the end of the baseline assessment

Intention to get the HIV vaccine, measured after inoculation intervention and misinformation exposure The intention to get the vaccine will be measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine.

At the end of the baseline assessment

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
HIV Vaccine Intention, Follow-up
Tijdsspanne: 2-4 weeks

Intention to get the HIV vaccine, measured at follow-up survey following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine.

2-4 weeks
Recommend to Friends, at the End of the Baseline Assessment
Tijdsspanne: At the end of the baseline assessment

Intention to recommend the HIV vaccine to friends, measured at survey baseline following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend.

At the end of the baseline assessment
Recommend to Friends, Follow-up
Tijdsspanne: 2-4 weeks

Intention to recommend the HIV vaccine to friends, measured at follow-up survey following misinformation exposure and intervention, controlling for baseline pre-intervention/exposure intention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend.

2-4 weeks
Credibility of Inoculated Exposure #1
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #2
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #3
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #3 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #4
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #4 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #5
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #5 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #6
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #6 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #1
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #2
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #3
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #3 made the participants anxious or nervous about the HIV vaccine. TThey were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #4
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #4 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #5
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #5 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #6
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #6 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Shareability of Inoculated Exposure #1
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #7
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #7 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #3
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #3 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #4
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #4 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #5
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #5 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #6
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #6 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #1, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of Inoculated Exposure #2, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Shareability of Inoculated Exposure #1, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of Inoculated Exposure #2, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Anxiousness of Inoculated Exposure #1, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of Inoculated Exposure #2, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Credibility of New Claims, Exposure #12, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #12 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #8, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #8 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #9, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #9 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #10, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #10 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #11, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #11 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Anxiousness o of New Claims, Exposure #12, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #12 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Claim #8, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #8 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #9, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #9 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #10, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #10 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #11, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #11 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Shareability of New Claims, Exposure #12, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #12 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #8, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #8 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #9, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #9 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #10, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #10 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #11, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #11 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Credibility of Inoculated Exposure #7
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #7 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #7
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #7 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Shareability of Inoculated Exposure #2
Tijdsspanne: At the end of the baseline assessment

Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Credibility of New Claims, Exposure #13, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #13 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Anxiousness of New Claims, Exposure #13, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #13 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Shareability of New Claims, Exposure #13, Follow-up
Tijdsspanne: 2-4 weeks

Extent to which claim #13 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

24 juli 2025

Primaire voltooiing (Werkelijk)

16 oktober 2025

Studie voltooiing (Geschat)

1 juni 2027

Studieregistratiedata

Eerst ingediend

7 november 2024

Eerst ingediend dat voldeed aan de QC-criteria

18 november 2024

Eerst geplaatst (Werkelijk)

22 november 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

24 september 2026

Laatste update ingediend die voldeed aan QC-criteria

28 augustus 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 1R01MH132401 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

The investigators are still determining the data sharing plan and if we will be sharing IPD yet

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren